Table 3

Postoperative Outcomes for Rhizotomy, Balloon Ablation, and MVD


BA
MVD
Rhizotomy
Combined

Hospital Length of Stay (Days)
2.6 ± 0.4
5.7 ± 0.6 *
4.3 ± 0.2
5.0 ± 0.3
Without Complications (Days)
0.5 ± 0.1
4.6 ± 0.6
3.3 ± 0.3

Length of Follow-up (Months)
21.8 ± 3.2
33.4 ± 7.1
21.0 ± 4.9
26.5 ± 42
Incidence of Immediate Improvement in Symptoms
56/78 (72%)
31/34 (91%) *
35/41 (85%) *
66/75 (88%)
Improvement of Symptoms with Bradycardia
75%
87%
80%
84%
Incidence of Total Cure
31/78 (40%) **
23/34 (68%)
22/41 (54%) **
45/75 (60%)
Incidence of No Change in Symptoms
21/78 (27%)
2/34 (6%) *
6/41 (15%) *
8/75 (11%)*
Incidence of Requirement for Post-Op Medications to Treat TN
45/77 (58%) **
8/34 (24%)
21/41 (51%)
29/75 (39%)
Incidence of Post-operative Relapse
8/83 (10%)
4/37 (11%)
4/43 (9%)
8/75 (10%)
Incidence of need to have re- operation
22/78 (28%)
3/34 (9%) *
2/42 (5%) *
5/76 (7%)
Time Until Relapse (Months)
12.1 ± 3.1
10.6 ± 8.5
6.3 ± 1.2
8.4 ± 4.1
Number of Patients Lost to Follow-up (%)
7/82 (9%)
5/37 (14%)
4/43 (9%)
9/80 (11%)

* P < 0.05 compared to BA

** P < 0.05 compared to MVD

All data reported as mean ± SEM

Combined = Microvascular Decompression with or without Rhizotomy

Jellish et al. Head & Face Medicine 2008 4:11   doi:10.1186/1746-160X-4-11